Date: 2015-08-05
Type of information: Nomination
Compound:
Company: Halozyme Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 5, 2015, Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, announced the appointment of Jeffrey W. Henderson to its board of directors. Henderson served as CFO of Cardinal Health from 2005 until late last year, playing a key role in the company\'s growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Henderson also managed commercial operations in China and Canada. Prior to Cardinal Health, Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Henderson is a native of St. Catharines, Ontario, Canada.
Financial terms:
Latest news:
